Contact

Menu

Article

Technology transforming the transplantation process

Several solutions have been proposed to shorten the waiting time for transplant patients and make more organs available, including a move from explicit to presumed consent (a new opt-out system). How can technology facilitate the organ transplantation process and help save people’s lives?

December 14, 2023

Thomas Amrein

CFA, Senior Portfolio Manager

Key takeaways

Due to scarcity, not enough donor organs are available for patients qualified for transplantation. As a result, these patients' health often deteriorates significantly while they are waiting for an organ transplant.

The main reason for the shortage of organs is the fact that too many donated organs go unused, which is costing lives.

A technological breakthrough can significantly increase the utilization of organs available for transplantation, thus enabling patients to get their organ transplant much sooner.

Patients who need an organ transplant usually have to wait long for the live-saving procedure. And time is a luxury they cannot afford. They are put on waiting lists while their health continues to severely deteriorate. Several solutions have been proposed to shorten the waiting time for transplant patients and make more organs available, including a move from explicit to presumed consent (a new opt-out system). Yet, there are still not enough donors or organs viable for donation. 

How can technology facilitate the organ transplantation process and help save people’s lives?

More than 103,000 patients are waiting for an organ transplant in the US alone

Organ donation and transplantation is a surgical process during which a failing organ is replaced with a healthy one. Organ recipients are usually patients who are critically ill in the end stages of organ failure. Undergoing an organ transplant can prolong a person’s life, giving those with a chronic illness a chance to reach the average lifespan.

"Many people need an organ transplant due to a genetic condition such as polycystic kidney disease, cystic fibrosis, or a heart defect. Infections such as hepatitis, physical injuries to organs, and damage due to chronic conditions such as diabetes may also cause a person to require a transplant"

Unbox the Future

Powerful megatrends have the potential to change every facet of our daily lives. Join our award-winning investment team in their pursuit of identifying the most innovative pure-play companies that may add long-term growth potential and portfolio diversification. 

 

According to preliminary data from United Network for Organ Sharing (UNOS), which serves as the national Organ Procurement and Transplantation Network under federal contract, 42,887 organ transplants were performed in the US in 2022 – an increase of 3.7% from 2021 and a new annual record.2 Impressive as this number may seem, it accounts for less than half of the people who still need organ transplants.

In the US alone, more than 103,000 people are currently on organ transplant waiting lists and every day 17 of them die waiting for an organ transplant.3

Thousands of donated organs go unused, costing lives

Every year, thousands of donated organs go to waste, particularly lungs, hearts, and livers (see Figure 1). On top of the scarcity of viable organs, not all donated organs are utilized – further exacerbating the problem of availability. But why do they go to waste?

Generally speaking, there are two types of organ donations from recently deceased patients: donation after brain death (DBD) and donation after circulatory death (DCD). Traditionally, donation after brain death is more common than donation after circulatory death, since the quality of organs obtained after circulatory death can, at times, be difficult to assess.4

Figure 1: The proportion of unused donated organs

The proportion of unused donated organs

Sources: Credit Suisse, Transmedics. Based on: Transmedics (2023). Transforming Organ Transplantation Therapy Worldwide. Investor presentation May 2023. Page 5. Link; retrieved on November 15, 2023

Although more and more donors are registered in the system, the percentage of utilized organs is very low. As a result, the organ shortage and the recipient waiting lists will likely persist. Traditionally, when in doubt, a surgeon would rather reject an organ ahead of the procedure rather than just before the transplantation if they are not confident about its viability, since any transplant complications adversely affect their statistics. This is often the case when an organ has been obtained after circulatory death – since it is often difficult to assess the quality of such an organ, it is often discarded at some stage of the transplantation process.

Thematic Investments

Our investment teams identify and aim to invest in exciting and attractively valued companies that are on the cutting edge of innovation. Join us and invest in tomorrow’s winners.

Organ Care System to optimize organ transportation

Hypothermia remains one of the most common ways of preserving donated organs today. Donated organs are transported to a recipient for transplant stored in organ-preservation fluid, cooled with ice, and transported in a cooler. However, this method is not ideal because the transported organ can suffer damage and it is often hard to assess its viability prior to transplantation.

Here is where technology can help. The Organ Care System (OCS) is a medical device that allows donated organs, including heart, lung, or liver, to be kept in a metabolically active state. It not only keeps the organ in much better condition as time passes, which makes it viable for longer, but it also allows for the organ viability assessment just before the transplantation, thus increasing the chances for the success of the procedure.

Figure 2: The Organ Care System keeps organs working

Sources: Credit Suisse, Transmedics. Based on: Transmedics (2023). Transforming Organ Transplantation Therapy Worldwide. Investor presentation May 2023. Page 5. Link; retrieved on November 15, 2023

Promising results of clinical trials led to broad FDA label 

Before the OCS was approved for broad use, it had to be evaluated by the Food and Drug Administration (FDA). FDA approval means that data on the effects of using a given drug or equipment have been reviewed and are a proof that the benefits of using the drug or equipment outweigh their known and potential risks. Clinical evidence is necessary to support the claim. Without hard data and FDA approval, it is highly unlikely that transplant centers would change their current practices and start using the OCS. 

Figure 3: Clinical outcomes

OCSTM Lung
Clinical Outcomes
OCSTM Heart
Clinical Outcomes
OCSTM Liver
Clinical Outcomes
87%
Utilization of unused lungs from DBD &DCD donors – good ourcomes
81%
Utilization of unused hearts from DBD donors – good ourcomes
2x
Rate of DCD donor liver utilization
50%
Reduction of severe post‑transplant complications

65%
Lower5 severe post‑transplant complications

 

95%
Patient survivale aftetr DCD donor heart transplants

 

43%
Reduction of severe post‑transplant complications

 

84%
Reduction in long‑term biliary complications

Sources: Credit Suisse, Transmedics. Based on: Transmedics (2023). Transforming Organ Transplantation Therapy Worldwide. Investor presentation May 2023. Page 8. Link; retrieved on November 15, 2023

Clinical tests conducted with the use of OCS provided very promising results: the utilization of lungs and hearts exceeded 80%, while severe post-transplant complications were reduced by 50% and 65% for lungs and hearts respectively. The utilization of donor livers doubled, with a 43% reduction of severe post-transplant complications. Every organ wasted is a life not saved – by increasing the percentage of utilized organs, the OCS can give more patients a chance for a transplant that may save their lives. As a result of the clinical trials, the FDA approved the OCS for use, thus helping to transform the transplantation process.

Figure 4: Utilization of organs with OCS systems

organ-transplantation-digital-health-utilisation-of-organs-with-ocs-systems-en.jpg

Sources: Credit Suisse, Transmedics. Based on: Transmedics (2023). Transforming Organ Transplantation Therapy Worldwide. Investor presentation May 2023. Page 7. Link; retrieved on November 15, 2023

Technology is transforming organ transplantation

While numerous healthcare technologies are still in the developmental stage, the OCS has already started transforming the organ donation and transplantation system across many of the best-known transplantation centers in the US and all over the world. More organs available for transplantation means shorter wait time for patients and better planning and more efficient work for doctors. 

Credit Suisse Asset Management has designed several highly focused strategies to provide clients with "pure-play"7 exposure to a number of compelling long-term secular growth themes, such as robotics and automation, security and safety, infrastructure, digital health, edutainment, environmental impact, and energy evolution.

Investment possibilities

Find investment products that suit your personal needs. Choose from our extensive range of investment solutions across all major asset classes, and access all product-related information.

You can also follow a fund and receive the monthly factsheet quickly and easily.

fundsearch-fund-updates-newsletter2.jpg

Get in touch with Asset Management

Contact us to learn about exciting investment opportunities. We are here to help you achieve your investment goals.

To the extent that these materials contain statements about the future, such statements are forward looking and are subject to a number of risks and uncertainties and are not a guarantee of future results/performance.

Every investment involves risk. You may lose part or all of invested capital.

The individuals mentioned above only conduct regulated activities in the jurisdiction(s) where they are properly licensed, where relevant.

1 MedicalNewsToday (2019). How organ transplants work. Retrieved from Everything you need to know about organ transplants (medicalnewstoday.com) on November 15, 2023
2 2022 organ transplants again set annual records (unos.org). Retrieved on November 15, 2023
Organ Donation Statistics | organdonor.gov. Retrieved on November 15, 2023
4 Harms of Unsuccessful Donation After Circulatory Death: An Exploratory Study - PMC (nih.gov). Retrieved on November 15, 2023
5 Nicoara A., et al. Primary graft dysfunction after heart transplantation: Incidence, trends, and associated risk factors; Am J Transplant. 2018;18:1461–1470.
6 Source – 2022 Organ Procurement & Transplant Network (OPTN) Data.
7 With the “pure-play” concept we mean companies which have at least 50% in revenues directly attributable to the corresponding theme.

This is a marketing communication.

Source: Credit Suisse, otherwise specified.
Unless noted otherwise, all illustrations in this document were produced by Credit Suisse AG and/or its affiliates with the greatest of care and to the best of its knowledge and belief.

This material constitutes marketing material of Credit Suisse AG and/or its affiliates (hereafter "CS"). This material does not constitute or form part of an offer or invitation to issue or sell, or of a solicitation of an offer to subscribe or buy, any securities or other financial instruments, or enter into any other financial transaction, nor does it constitute an inducement or incitement to participate in any product, offering or investment. This marketing material is not a contractually binding document or an information document required by any legislative provision. Nothing in this material constitutes investment research or investment advice and may not be relied upon. It is not tailored to your individual circumstances, or otherwise constitutes a personal recommendation, and is not sufficient to take an investment decision. The information and views expressed herein are those of CS at the time of writing and are subject to change at any time without notice. They are derived from sources believed to be reliable.CS provides no guarantee with regard to the content and completeness of the information and where legally possible does not accept any liability for losses that might arise from making use of the information. If nothing is indicated to the contrary, all figures are unaudited. The information provided herein is for the exclusive use of the recipient. The information provided in this material may change after the date of this material without notice and CS has no obligation to update the information. This material may contain information that is licensed and/or protected under intellectual property rights of the licensors and property right holders. Nothing in this material shall be construed to impose any liability on the licensors or property right holders. Unauthorised copying of the information of the licensors or property right holders is strictly prohibited. This material may not be forwarded or distributed to any other person and may not be reproduced. Any forwarding, distribution or reproduction is unauthorized and may result in a violation of the U.S. Securities Act of 1933, as amended (the “Securities Act”). In addition, there may be conflicts of interest with regards to the investment. In connection with the provision of services, Credit Suisse AG and/or its affiliates may pay third parties or receive from third parties, as part of their fee or otherwise, a one-time or recurring fee (e.g., issuing commissions, placement commissions or trailer fees). Prospective investors should independently and carefully assess (with their tax, legal and financial advisers) the specific risks described in available materials, and applicable legal, regulatory, credit, tax and accounting consequences prior to making any investment decision.
Singapore: This document is not a prospectus as defined in the Securities and Futures Act 2001 of Singapore ("SFA") and has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply, and this document should not be construed in any way as a solicitation or an offer to buy or sell any interest or investment referred to in this document.
Copyright © 2023 CREDIT SUISSE. All rights reserved.

Distributor AM: Credit Suisse (Singapore) Limited, 1 Raffles Link #03/#04-01 South Lobby Singapore, 039393 Singapore; Part of UBS Group
Distributor PB: Credit Suisse AG, Singapore Branch, 1 Raffles Link #03-01 One Raffles Link Singapore, 039393 Singapore; Part of UBS Group